A small version of Cordis Corp.‘s Cypher drug-eluting stent won approval from the Food & Drug Administration for treating blockages in small blood vessels.
The Bridgewater, N.J.-based Johnson & Johnson subsidiary said the federal watchdog’s approval of its 2.25mm Cypher sirolimus-eluting coronary stent was based on a quartet of studies comparing it to bare-metal stents.